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The oral antiplatelet agent clopidrogel has been widely used
by interventional cardiologists for the past two years as an
adjunct therapy to prevent subacute thrombosis after coro-
nary stenting. Interestingly, the substitution of clopidrogel
for ticlopidine occurred even though no conclusive data
existed to demonstrate the efficacy and safety of clopidrogel
for this indication, and despite two well-performed ran-
domized trials that clearly established ticlopidine as effec-
tive. This replacement in clinical practice of a proven agent
with an unproved one, prescribed off-label, was justified by
the infrequent but severe toxicity of ticlopidine. Clopidrogel
and its analogue ticlopidine have similar thienopyridine
structures. Both block platelet aggregation induced by
adenosine diphosphate and the subsequent transformation
of the glycoprotein IIb/IIIa receptor into its high affinity
state. Each also inhibits platelet aggregation in response to
collagen, thrombin and shear stress. In this issue of JACC,
Berger et al. (1) and Mishkel et al. (2) present single-center,
observational studies that confirm the clinical impression
that this is an appropriate substitution.
See pages 1884 and 1891
Now that there is data to support current practice, one
might wonder if the issue was ever seriously in doubt (3).
Clinical cardiologists commonly interchange one drug for
another of the same class (e.g., beta-blockers, angiotensin-
converting enzyme inhibitors). In this case, one drug has
serious side effects whereas the other does not. So, what was
the question? In fact, the story of antiplatelet therapy after
stenting is unique in modern medical practice. With regard
to clopidrogel, it should be recognized that studies demon-
strating the efficacy of a drug classically precede its wide-
spread clinical use; it is not common for them to follow an
intuitive substitution that is already standard. Prescribing
agents that are unproven for a certain indication when an
effective agent is available raises the question as to why
randomized trials are necessary, and why drug companies
should sponsor them. What happened to “evidence-based”
medicine?
The evolution of antithrombotic and antiplatelet therapy
in coronary stenting partially explains the milieu in which
interventionists made the decision to change drug regimens
without a randomized trial. The best medical regimen to
prevent stent thrombosis has long been a subject of inves-
tigation because of the tendency for the metallic struts to
abet clot formation. Very aggressive, early, empiric drug
combinations decreased the rate of thrombosis but were
associated with a high incidence of bleeding and vascular
complications. The original drug regimen approved by the
Food and Drug Administration involved a prolonged pro-
tocol of aspirin, dipyridamole, dextran, heparin and couma-
din. Subsequently, various less rigorous regimens were
proposed that were designed to decrease the bleeding risk,
yet, together with high pressure balloon inflations, diminish
the chance of stent thrombosis. The ticlopidine/aspirin
combination quickly gained widespread acceptance soon
after preliminary presentations of two randomized trials at
scientific meetings (4,5), several years before their formal
publication (6,7). When labeling lags so far behind dynam-
ically occurring improvements, conditions are created where
clinicians feel compelled to alter their clinical practice and
ignore formal approval status.
Clinical studies using ticlopidine. Ticlopidine has a half-
life of ;12 h, requiring it to be given at a dose of 250 mg
twice daily to achieve steady state levels. It should ideally be
administered for at least three days before elective stenting,
although a loading dose of 500 mg twice daily for 48 h may
be used in urgent situations. After ticlopidine is stopped, the
antiplatelet effect gradually dissipates over one to two weeks.
Ticlopidine reduces the risk of myocardial infarction and
death in patients with unstable angina (8). In acute coronary
syndromes, ticlopidine reduces the risk of nonfatal or fatal
infarction at six months by 41%. It also decreases the risk of
stroke as compared with the use of aspirin (9).
Unfortunately, ticlopidine has uncommon (0.5% to 3.0%)
but very serious adverse effects, including neutropenia (1%
to 2.5%), thrombocytopenia, thrombotic thrombocytopenic
purpura (10), rash and hepatic cholestasis. In general, these
are reversible with discontinuation of the drug. In addition,
there are rare cases of aplastic anemia, bone marrow
suppression, pancytopenia and agranulocytosis (11). These
hematologic side effects almost always occur within several
months after the initiation of therapy, and consequently,
complete blood counts should be performed every two
weeks during the first three months of therapy with this
agent (12). However, it is unlikely that this routine surveil-
lance would be useful in detecting thrombotic thrombocy-
topenic purpura, as the platelet counts can be normal just
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two weeks before the onset of this disease (10). The drug
also commonly produces nausea, vomiting and diarrhea,
which can be ameliorated if taken with meals. An elevation
in cholesterol and a decrease in plasma fibrinogen are
frequent after long-term administration.
In a randomized trial in which balloon percutaneous
transluminal coronary angioplasty was performed, ticlopi-
dine reduced the incidence of ischemic complications more
than an aspirin plus dipyridamole combination (2% vs. 5%)
(13). In the Intracoronary Stenting And Thrombotic Reg-
imen (ISAR) trial, which compared aspirin plus ticlopidine
versus aspirin plus coumadin after stenting, less fever,
bleeding and acute ischemic complications were noted at 30
days in the ticlopidine group (6). Among high risk patients,
ticlopidine decreased stent thrombosis (0% vs. 11.5%) and
major adverse clinical events (MACE) at 30 days (2.0% vs.
12.6%). In the randomized, multicenter Stent Anticoagula-
tion Regimen Study (STARS) (7), ticlopidine plus aspirin
was associated with significantly fewer cases of subacute
stent thrombosis and MACE than aspirin alone or aspirin
plus warfarin. Although therapy with ticlopidine plus aspi-
rin continued for four weeks, patients with coronary stents
have often been treated with ticlopidine for shorter dura-
tions. The length of therapy was empirically altered from
four weeks to three weeks, and frequently to two weeks by
many physicians in response to its toxicity and the need for
serial blood testing. The duration of the ticlopidine drug
regimen was already being altered in Europe at the time the
randomized trials were being presented (4,5), and the drug
was essentially replaced in practice by the time STARS (7)
was published.
Clinical studies using clopidrogel. Clopidrogel is admin-
istered once per day and has a more favorable side-effect
profile as compared with ticlopidine. The overall tolerability
is similar to aspirin and its hematologic effects are minimal.
Its general clinical efficacy was tested in the Clopidrogel
versus Aspirin in Patients at Risk of Ischemic Events
(CAPRIE) trial (14), which was a 304-center trial of 19,185
patients randomized to either 75 mg/day of clopidrogel or
325 mg/day aspirin, treated for an average of 1.6 years.
Efficacy for the secondary prevention of adverse cardiovas-
cular events in patients with previous stroke, myocardial
infarction or peripheral vascular disease was shown by the
relative risk reduction of 8.7% for clopidrogel versus aspirin
(p 5 0.45), which is itself an active agent in reducing
cardiovascular events. No increased incidence of leukopenia,
thrombocytopenia or gastrointestinal side effects were ob-
served. Clopidrogel has not been compared with aspirin or
anticoagulant agents in acute coronary syndromes or coro-
nary stenting in randomized trials.
Current studies. Berger et al. (1) used an historical control
design to study the clinical outcomes of coronary stenting in
500 consecutive patients who received a combination of
clopidrogel and aspirin, and 827 consecutive patients from
an earlier time frame who had received a combination of
ticlopidine and aspirin for a total of 14 days after oral
loading just before stent implantation. The baseline char-
acteristics were similar between the two groups, other than
the fact that the majority of patients who received clopidro-
gel had different kinds of stents implanted than the patients
who received ticlopidine (an important treatment bias),
reflecting the disparate dates at which stenting was per-
formed. In this study, the combination of clopidrogel and
aspirin was found to be safe and effective and associated
with a very low incidence of MACE (0.8% vs. 1.3%) and
subacute stent thrombosis (0.2% vs. 0.7%) as compared with
the combination of ticlopidine and aspirin at 30 days.
Mishkel et al. (2) studied a total of 875 patients treated
concurrently over a five-month period; 514 received clo-
pidrogel plus aspirin and 361 received ticlopidine plus
aspirin for two to four weeks. Only 66% were pretreated,
none with a loading dose, and the agents were selected
according to operator discretion. At 30 days, a similar
incidence of MACE (2.1% vs. 1.4%) and subacute throm-
bosis (0.2% vs. 0.7%) was observed. It is remarkable that all
three patients with acute stent thrombosis were in the
clopidrogel group, none of whom had received their first
dose. This is a complex issue, as “intention-to-treat” analysis
is meaningless when there is no formal protocol and when
the agent selected is a function of operator discretion instead
of randomization. Although two of these patients had
received abciximab, it is unclear why operators would place
a stent without pretreatment with one of these antiplatelet
agents and aspirin. Two subacute stent thrombosis cases
occurred at days 12 and 20, events Berger et al. (1) state are
“very rare.” Finally, four of the five serious thrombotic
events, five of the seven deaths, five of the seven nonfatal
myocardial infarctions and three of the four urgent repeat
revascularizations occurred in the clopidrogel group. Al-
though this is statistically insignificant, these are disturbing
trends.
The biggest problem with both studies is that neither
proves equivalence. It should be recognized that although
both studies showed no statistically significant difference in
30-day outcome, this does not demonstrate that the two
drugs are equivalent. Efficacy trials are not usually powered
to assess relative adverse events rates, often resulting in large
confidence intervals bounding the relative risk of an adverse
event, as is evident in Table 3 of Mishkel et al. (2).
Consequently, the lack of a statistically significant difference
is not proof of equivalence, just that no difference is
discernible, especially when the 30-day clinical event rates
are so infrequent (16 of 875 patients in Mishkel’s study [2]
and 17 of 1,327 patients in Berger’s study [1]). As the
discussions in both studies note, a much larger series would
be required to meet this standard.
Other studies of clopidrogel in coronary stenting.
Moussa et al. (15) reported the outcomes in 283 consecutive
patients who received the clopidrogel/aspirin combination
as compared with 1,406 consecutive patients, also from
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another period, who received ticlopidine plus aspirin. Clo-
pidrogel was administered as a 300-mg loading dose fol-
lowed by 75 mg/day for four weeks. At one-month follow-
up, data were available for 269 patients who received
clopidrogel and for 1,313 patients who received ticlopidine,
or ;95% of the patient cohort. Event rates at one month
were not different between the two patient groups, including
the incidence of subacute stent thrombosis (1.4% vs. 1.5%,
p 5 NS) and MACE (2.4% vs. 3.1%, p 5 NS). In addition,
there was a lower incidence (5.3% vs. 10.6%, p 5 0.006) of
rash and diarrhea and no reports of bone marrow suppres-
sion with clopidrogel, whereas there were four reported
cases (0.3%) of neutropenia with ticlopidine. Jauhar et al.
(16) presented a prospective registry of 240 consecutive
patients who underwent coronary stent procedures treated
with clopidrogel/aspirin. In this patient cohort, in-hospital
complications and clinical outcomes at 30 days were excel-
lent, as only two patients had any adverse event. One patient
experienced late acute myocardial infarction and death;
however, angiography before death identified that the stent
site was patent. The second patient had a subacute throm-
bosis of the stent in the left main coronary artery; the patient
was treated interventionally and was ultimately discharged.
The 30-day follow-up was obtained in 96% of the patient
cohort. Two additional patients experienced subacute
thrombosis. None of the patients had any further target
vessel revascularization or late MACE. There were no
significant adverse bleeding events or vascular complica-
tions. Rash occurred in 4% of the patients, but neutropenia
was not observed.
Ongoing clinical trials. Current prospective, randomized
trials using clopidrogel in stenting are designed to show
improved safety rather than efficacy with the use of ticlopi-
dine. The Clopidrogel/Aspirin Stent International Cooper-
ative Study (CLASICS) was a randomized, double-blind,
three-armed study of 1,020 patients conducted in 48 Euro-
pean centers that was completed in December 1998 and
presented at the March 1999 meeting of the American
College of Cardiology. The aim of the study was to assess
the safety of two dosages of clopidrogel plus aspirin as
compared with the standard ticlopidine plus aspirin regimen
at 28 days. The clopidrogel groups included a high dose
cohort that received 300 mg intravenously followed by oral
therapy, and a standard dose group with no load. There was
no difference in MACE between the groups, but the study
was not powered to find one. Both clopidrogel groups had
fewer major adverse side effects than the ticlopidine group
(4.6% vs. 9.1%). Further, the standard low dose clopidrogel
group had a higher event rate than the group given the
loading dose (6.3% vs. 2.9%). Thus, the study concluded
that clopidrogel plus aspirin is safer than ticlopidine plus
aspirin and that intravenous loading is safe in the catheter-
ization laboratory setting. Another randomized trial,
CREDO, is in the start-up phase and is designed to
determine whether clopidrogel loading should be recom-
mended and to establish the appropriate length of therapy
(one month vs. one year).
Is a randomized study necessary? Because most interven-
tional cardiologists in the U.S. currently use clopidrogel
rather than ticlopidine, do the studies by Berger et al. (1)
and Mishkel et al. (2) offer sufficient data to constitute
definitive evidence supporting the use of clopidrogel in stent
recipients, even though the randomized, controlled studies
proving efficacy were performed with ticlopidine? Both
studies reflect data applicable to any “real world” clinical
interventional practice. Together with the study by Moussa
et al. (15), they strongly suggest that clopidrogel and
ticlopidine have equivalent clinical efficacy, but that the
advantage of clopidrogel is its diminished toxicity. These
conclusions match the widespread clinical experience, but
the level of evidence is still only modest (level 3), and thus
lacks precision and is subject to change.
With the publication of the studies by Berger et al. (1)
and Mishkel et al. (2), as well as the presentation of
CLASICS, interventionists can feel assured that their
choice to use clopidrogel is reasonable. However, the
questions of when and by which route loading should be
initiated and how long therapy should be continued, remain
unanswered. More importantly, if another agent of the same
class with a perceived benefit were introduced now, should
it be accepted after preliminary data are obtained, or is a
randomized trial required first? This issue has important
regulatory and legal ramifications that seem disconnected
from clinical practice, where the precedent is clear. The
cardiology community must set and follow high standards of
proof for new therapy and support efforts that do provide
this level of evidence, even when such a “stodgy” approach
may temporarily delay the introduction of better therapy in a
rapidly changing therapeutic environment. As yet, there is no
substitute for the appropriately designed, randomized trial.
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